Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: Meta-Analysis of randomised controlled trials

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1964-1970

  Zou, Kun ^a,b   Wong, Jean ^c   Abdullah, Natasya ^a   Chen, Xi ^a   Smith, Toby ^d   Doherty, Michael ^a   Zhang, Weiya ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Affiliated Cancer Hospital of University of Electronic Science and Technology of China   (China)

^c Pinfold Medical Practice   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Epidemiology; Osteoarthritis; Treatment

Indexed keywords

CHONDROITIN; CORTICOSTEROID; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTICLE; FUNCTIONAL STATUS; HEALTH CARE CONCEPTS; HUMAN; LAVAGE; META ANALYSIS; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PROPORTION ATTRIBUTABLE TO CONTEXTUAL EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGIDITY; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ANALGESIA; ARTHRALGIA; COMPLICATION; FEMALE; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED;

ARTHRALGIA; FEMALE; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC IRRIGATION; TREATMENT OUTCOME;

EID: 84959422786     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208387     Document Type: Article

References (25)

1. Wampold BE, Minami T, Tierney SC, et al. The placebo is powerful: estimating placebo effects in medicine and psychotherapy from randomized clinical trials. J Clin Psychol 2005;61:835-54
2. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-Analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716-23
3. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthr Cartil 2009;17:1255-62
4. Di Blasi Z, Harkness E, Ernst E, et al. Influence of context effects on health outcomes: A systematic review. Lancet 2001;357:757-62
5. Crow R, Gage H, Hampson S, et al. The role of expectancies in the placebo effect and their use in the delivery of health care: A systematic review. Health Technol Assess 1999;3:1-96
6. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7
7. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
8. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
9. NICE. Osteoarthritis Care and management in adults. 2014. http://www.nice.org.uk/nicemedia/live/14383/66527/66527.pdf (accessed 28 Jul 2015)
10. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009 Osteoarthr Cartil 2010;18:476-99
11. Wandel S, Jöni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-Analysis. BMJ 2010;341: c4675
12. Walach H. The efficacy paradox in randomized controlled trials of CAM and elsewhere: Beware of the placebo trap. J Altern Complement Med 2001;7:213-18
13. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
14. Borenstein M, Hedges LV, Higgins JPT, et al. Effect Sizes Based on Means Introduction to meta-Analysis. Chichester, UK: John Wiley & Sons, 2009:21-32
15. Juhl C, Lund H, Roos EM, et al. A hierarchy of patient-reported outcomes for meta-Analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. Arthritis 2012;2012:136245
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12
17. Hedges LV, Gurevitch J, Curtis PS. The meta-Analysis of response ratios in experimental ecology. Ecology 1999;80:1150-6
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-Analysis. Stat Med 2002;21:1539-58
19. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997;315:629-34
20. Nöesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-Analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515
21. Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: A meta-Analysis of antidepressant medication. Prev Treat 1998;1:Article 0002a
22. Walach H, Sadaghiani C, Dehm C, et al. The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials-A secondary analysis. BMC Med Res Methodol 2005;5:26
23. Hill AB. Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials 1990; 11:77-9
24. Abhishek A, Doherty M. Mechanisms of the placebo response in pain in osteoarthritis. Osteoarthr Cartil 2013;21:1229-35
25. Colloca L, Lopiano L, Lanotte M, et al. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004;3:679-84